Brainstorm Cell Therapeutics Inc. (BCLI)
NASDAQ: BCLI · Real-Time Price · USD
1.260
+0.010 (0.80%)
Nov 20, 2024, 4:00 PM EST - Market closed
BCLI Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 8.68 | 10.69 | 10.87 | 9.3 | 9.36 | 5.8 | |
| Research & Development | 4.63 | 10.75 | 13.96 | 15.24 | 22.33 | 17.2 | |
| Operating Expenses | 13.31 | 21.44 | 24.82 | 24.54 | 31.68 | 23 | |
| Operating Income | -13.31 | -21.44 | -24.82 | -24.54 | -31.68 | -23 | |
| Interest Expense | -0.38 | -0.28 | - | - | -0.13 | -0.25 | |
| Interest & Investment Income | - | - | 0.55 | 0.08 | - | - | |
| Other Non Operating Income (Expenses) | -0.54 | 4.53 | - | - | - | - | |
| Pretax Income | -14.23 | -17.19 | -24.28 | -24.46 | -31.81 | -23.25 | |
| Net Income | -14.23 | -17.19 | -24.28 | -24.46 | -31.81 | -23.25 | |
| Net Income to Common | -14.23 | -17.19 | -24.28 | -24.46 | -31.81 | -23.25 | |
| Shares Outstanding (Basic) | 4 | 3 | 2 | 2 | 2 | 1 | |
| Shares Outstanding (Diluted) | 4 | 3 | 2 | 2 | 2 | 1 | |
| Shares Change (YoY) | 69.79% | 17.99% | 0.90% | 21.22% | 36.25% | 9.54% | |
| EPS (Basic) | -3.19 | -5.99 | -9.97 | -10.14 | -15.99 | -15.92 | |
| EPS (Diluted) | -3.19 | -6.00 | -9.97 | -10.20 | -15.99 | -15.92 | |
| Free Cash Flow | -11.35 | -20.48 | -19.35 | -26.6 | -35.57 | -11.72 | |
| Free Cash Flow Per Share | -2.55 | -7.13 | -7.95 | -11.03 | -17.88 | -8.03 | |
| EBITDA | -13.06 | -21.17 | -24.54 | -24.28 | -31.47 | -22.84 | |
| D&A For EBITDA | 0.25 | 0.27 | 0.29 | 0.26 | 0.22 | 0.16 | |
| EBIT | -13.31 | -21.44 | -24.82 | -24.54 | -31.68 | -23 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.